Biogen and Ionis Pharmaceuticals provide update on the development of Ionis-SMNrx
In response to numerous requests from the SMA community, Biogen and Ionis (previously ISIS) Pharmaceuticals, provide an update on the clinical development on their investigational compound, currently being tested in Phase 3 clinical trials.
To read the letter, please click here.